Literature DB >> 33394287

A computational approach to analyse the amino acid variants of GLB1 protein causing GM1 Gangliosidosis.

K Priyanka1, N Madhana Priya1, R Magesh2.   

Abstract

Lysosomal storage diseases comprise different forms of autosomal recessive disorders from which GM1 gangliosidosis has categorized by the accumulation of complex glycolipids associated with a range of progressive neurologic phenotypes. GM1 gangliosidosis is an inherited disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. GM1 has three main types of onsets, namely infantile (type I), juvenile (type II), and adult (type III) forms. This study provides a series of computational methods that examine the mutations that occurred in GLB1 protein. Initially, the mutational analysis started with 689 amino acid variants for a sequence-based screening and it was done with quite a few In-silico tools to narrow down the most significant variants by utilizing the standard tools; namely, Evolutionary analysis (77 variants), Pathogenicity prediction (44 variants), Stability predictions (30 variants), Biophysical functions (19 variants) and according to the binding site of protein structure with PDB ID 3THC, seven variants (Y83D, Y83H, Y270S, Y270D, W273R, W273D, and Y333H) were narrowed down. Structure based analysis was performed to understand the interacting profile of the native protein and variants with Miglustat; which is the currently used FDA drug as an alternative to enzyme replacement therapy. Molecular Docking study was done to analyze the protein interaction with Miglustat (ligand), as a result native (3THC) structure had a binding affinity of -8.18 kcal/mol and two variant structures had an average binding affinities of -2.61 kcal/mol (Y83D) and - 7.63 kcal/mol (Y270D). Finally, Molecular Dynamics Simulation was performed to know the mutational activity of the protein structures on Miglustat for 50,000 ps. The Y83D variant showed higher deviation than native protein and Y270D in all trajectory analysis. The analysis was done to the protein structures to check the structural variations happened through simulations. This study aids to understand the most deleterious mutants, the activity of the drug to the protein structure and also gives an insight on the stability of the drug with the native and selected variants.

Entities:  

Keywords:  Amino acid variants; GLB1; GM1 gangliosidosis; Miglustat; Molecular docking; Molecular dynamics

Year:  2021        PMID: 33394287     DOI: 10.1007/s11011-020-00650-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  18 in total

1.  ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information.

Authors:  Fabian Glaser; Tal Pupko; Inbal Paz; Rachel E Bell; Dalit Bechor-Shental; Eric Martz; Nir Ben-Tal
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

2.  The Clinical and Molecular Spectrum of GM1 Gangliosidosis.

Authors:  Laila Arash-Kaps; Katalin Komlosi; Marlene Seegräber; Stefan Diederich; Eduard Paschke; Yasmina Amraoui; Skadi Beblo; Andrea Dieckmann; Martin Smitka; Julia B Hennermann
Journal:  J Pediatr       Date:  2019-12       Impact factor: 4.406

3.  A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference.

Authors:  Anissa Leonard; Patrick Lebecque; Jasper Dingemanse; Teresinha Leal
Journal:  J Cyst Fibros       Date:  2012-01-27       Impact factor: 5.482

Review 4.  Lysosomal Glycosphingolipid Storage Diseases.

Authors:  Bernadette Breiden; Konrad Sandhoff
Journal:  Annu Rev Biochem       Date:  2019-06-20       Impact factor: 23.643

5.  GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.

Authors:  Doris Hofer; Karl Paul; Katrin Fantur; Michael Beck; Friederike Bürger; Catherine Caillaud; Ksenija Fumic; Jana Ledvinova; Agnieszka Lugowska; Helen Michelakakis; Briguita Radeva; Uma Ramaswami; Barbara Plecko; Eduard Paschke
Journal:  Hum Mutat       Date:  2009-08       Impact factor: 4.878

6.  Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.

Authors:  Umeharu Ohto; Kimihito Usui; Toshinari Ochi; Kenjiro Yuki; Yoshinori Satow; Toshiyuki Shimizu
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

7.  The Arg482His mutation in the beta-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village.

Authors:  Theodoros Georgiou; Goula Stylianidou; Violetta Anastasiadou; Anna Caciotti; Yvan Campos; Enrico Zammarchi; Amelia Morrone; Alessandra D'azzo; Anthi Drousiotou
Journal:  Genet Test       Date:  2005

8.  Gene Therapy Monitoring: Clinical Monitoring for Efficacy and Potential Toxicity.

Authors: 
Journal:  Mol Diagn       Date:  1997-06

Review 9.  GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects.

Authors:  Nicola Brunetti-Pierri; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2008-06-03       Impact factor: 4.797

10.  Computational protein-ligand docking and virtual drug screening with the AutoDock suite.

Authors:  Stefano Forli; Ruth Huey; Michael E Pique; Michel F Sanner; David S Goodsell; Arthur J Olson
Journal:  Nat Protoc       Date:  2016-04-14       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.